Maxim Group analyst Naz Rahman maintained a Buy rating on Clene (CLNN – Research Report) on February 2 and set a price target of $9.00. The company’s shares closed last Friday at $2.84, close to its 52-week low of $2.36.
According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -38.8% and a 4.3% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Vertex Pharmaceuticals, and Galmed Pharmaceuticals.
The the analyst consensus on Clene is currently a Moderate Buy rating.
See the top stocks recommended by analysts >>
Clene’s market cap is currently $177M and has a P/E ratio of -3.23.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CLNN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tottenham Acquisition I Ltd. is a blank check company. Its purpose is to acquire, engage in a share exchange, share reconstruct, amalgate, and purchase all substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities. The company was founded on November 13, 2017 and is headquartered Hong Kong.
Read More on CLNN:
- Maxim Group Thinks Entera Bio’s Stock is Going to Recover
- Maxim Group Thinks Enveric Biosciences’ Stock is Going to Recover
- Needham Thinks SailPoint Technologies Holdings’ Stock is Going to Recover
- Wells Fargo Keeps Their Hold Rating on Park Hotels & Resorts (PK)
- Alphabet Class C (GOOG) Gets a Buy Rating from Robert W. Baird
